# Phase 3 ovarian cancer trials recruiting: 47 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 47 trials in phase 3 for ovarian cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 ovarian cancer trials: 47 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/ovarian-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 47
- Recruiting or not yet: 47
- Read on: November 19, 2026

## Trials

The 25 newest of 47, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| October 5, 2026 | NCT07859215 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line... | Genmab | Phase 3 | Not yet recruiting | Ovarian Cancer | 602 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859215) |
| September 16, 2026 | NCT07822646 | A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer | Chinese PLA General Hospital | Phase 3 | Recruiting | Ovarian Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822646) |
| September 14, 2026 | NCT07816666 | Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer | AstraZeneca | Phase 3 | Recruiting | Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816666) |
| September 1, 2026 | NCT07797283 | Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing... | Incyte Corporation | Phase 3 | Not yet recruiting | Ovarian Cancer | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797283) |
| August 28, 2026 | NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent... | Daiichi Sankyo | Phase 3 | Not yet recruiting | Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791732) |
| August 21, 2026 | NCT07779538 | Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Recruiting | Ovarian Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779538) |
| August 20, 2026 | NCT07776691 | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Ovarian Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer | 802 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776691) |
| August 3, 2026 | NCT07743164 | A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 646 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743164) |
| July 10, 2026 | NCT07694427 | Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) \[BEHOLD-Ovarian03\] | GlaxoSmithKline | Phase 3 | Recruiting | Ovarian Neoplasms | 720 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694427) |
| July 6, 2026 | NCT07684612 | A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With... | GlaxoSmithKline | Phase 3 | Recruiting | Ovarian Neoplasms | 690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07684612) |
| May 22, 2026 | NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant... | Genmab | Phase 3 | Recruiting | Platinum-resistant Ovarian Cancer | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604766) |
| May 4, 2026 | NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based... | Genmab | Phase 3 | Recruiting | Platinum-Sensitive Ovarian Cancer, Ovarian Cancer | 688 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564141) |
| April 22, 2026 | NCT07546500 | A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian... | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Phase 3 | Recruiting | Ovarian Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546500) |
| April 22, 2026 | NCT07544030 | A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy... | Sponsor not shown (see the record) | Phase 3 | Recruiting | Ovarian Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07544030) |
| January 6, 2026 | NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Ovarian Neoplasms, Ovarian Cancer | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318558) |
| December 16, 2025 | NCT07286266 | A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer... | GlaxoSmithKline | Phase 3 | Recruiting | Ovarian Neoplasms | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286266) |
| December 16, 2025 | NCT07286162 | Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer | University Health Network, Toronto | Phase 3 | Not yet recruiting | Ovarian Cancer (OvCa), Recurrent Ovarian Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07286162) |
| November 6, 2025 | NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of... | Genmab | Phase 3 | Recruiting | Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC | 544 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225270) |
| October 9, 2025 | NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C)... | Eli Lilly and Company | Phase 3 | Recruiting | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis | 1,630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213804) |
| July 16, 2025 | NCT07068464 | ICRA Randomised Controlled Trial | NHS Grampian | Phase 3 | Not yet recruiting | Ovary Cancer | 682 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07068464) |
| May 25, 2025 | NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | Tongji Hospital | Phase 3 | Not yet recruiting | Ovarian Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06990503) |
| May 8, 2025 | NCT06963268 | Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II) | Instituto de Investigacion Sanitaria La Fe | Phase 3 | Recruiting | Ovarian Neoplasms | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963268) |
| May 1, 2025 | NCT06954584 | Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer | Tongji Hospital | Phase 3 | Recruiting | Ovarian Cancer | 424 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06954584) |
| April 7, 2025 | NCT06915025 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly... | Imunon | Phase 3 | Recruiting | Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06915025) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 4 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 4 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 3 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 2 |
| [Suzhou Suncadia Biopharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/suzhou-suncadia-biopharmaceuticals-co-ltd) | 2 |
| Tongji Hospital | 2 |
| Imunon | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| NHS Grampian | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Fudan University | 1 |
| The First Affiliated Hospital of Xiamen University | 1 |
| University Health Network, Toronto | 1 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 1 |
| NRG Oncology | 1 |
| Charles University, Czech Republic | 1 |
| National Cancer Center, Korea | 1 |
| Chinese PLA General Hospital | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| Centre Francois Baclesse | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| [Jiangsu Alphamab Biopharmaceuticals Co., Ltd](https://specstream.ai/data/clinical-trials/company/jiangsu-alphamab-biopharmaceuticals-co-ltd) | 1 |
| Instituto de Investigacion Sanitaria La Fe | 1 |
| National Cancer Institute, Naples | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 16 |
| South Korea | 13 |
| Japan | 12 |
| Australia | 10 |
| Italy | 10 |
| Canada | 10 |
| France | 8 |
| Spain | 8 |
| Taiwan | 8 |
| United Kingdom | 8 |
| Germany | 7 |
| Belgium | 6 |
| Brazil | 6 |
| Denmark | 6 |
| Israel | 6 |
| Poland | 6 |
| Finland | 6 |
| Austria | 5 |
| Czechia | 5 |
| Greece | 4 |
| Hungary | 4 |
| Argentina | 4 |
| Ireland | 4 |
| Netherlands | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Refinishing companies in the United States](https://specstream.ai/data/businesses/refinishing-companies/united-states)
- [Energy companies in the United States](https://specstream.ai/data/businesses/energy-companies/united-states)
- [Tax preparation firms in the United States](https://specstream.ai/data/businesses/tax-preparation-firms/united-states)
- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
